Alnylam Pharma Re-elects Directors at Annual Meeting

Alnylam Pharma ( (ALNY) ) just unveiled an update.

On March 10, 2025, Alnylam Pharma held its Annual Meeting where stockholders re-elected four Class III directors to serve until 2028. Additionally, stockholders approved several key proposals, including a Certificate of Amendment, the Second Amended and Restated 2018 Stock Incentive Plan, and the compensation of named executive officers. PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Spark’s Take on ALNY Stock

According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.

Alnylam Pharmaceuticals scores 62, reflecting its robust revenue growth and promising future prospects in the biotechnology sector. While strong liquidity and strategic growth initiatives are positives, the company faces significant challenges with profitability, high leverage, and valuation metrics. The earnings call highlights a positive outlook, yet regulatory uncertainties and R&D expenses pose ongoing risks. Technical analysis supports a neutral to positive trend, but the negative P/E ratio underscores financial challenges.

To see Spark’s full report on ALNY stock, click here.

More about Alnylam Pharma

Average Trading Volume: 993,220

Technical Sentiment Signal: Strong Buy

Current Market Cap: $35.23B

See more data about ALNY stock on TipRanks’ Stock Analysis page.